Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?
Execs On The Move: Butterfly Network Brings On New Board Members
Butterfly Network has new chief information and technology officers, Sense Biodetection has a new CEO, and more.
More from Leadership
• By
Synchron is preparing a pilot study of its fully wireless, second-gen brain-computer interface after an ALS patient controlled an iPad solely by thought. If all goes as planned, Synchron’s BCI will move into pivotal trials in 2026.
• By
Apreo Health CEO Karun Naga talks to Medtech Insight about the company’s intentions for its Series B funding. The Breathe-3 clinical trial and early commercialization activities, involving physician education, are top priorities.
• By
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
• By
Exact Sciences has entered into an exclusive licensing agreement with Freenome, stipulating clinical benchmarks and a first-line rating in the USPSTF guidelines. Medtech Insight interviewed screening CMO Paul Limburg about CRC screening and Exact’s strategy on liquid biopsy.
More from Medtech Insight
• By
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
• By
The National Advertising Division (NAD) alerted Agendia to improve disclosure regarding a physician endorsing its MammaPrint test. The physician's ties to Agendia were inadequately revealed in LinkedIn posts.
• By
Just a year and four months after publishing a final rule that would have allowed it to regulate laboratory developed tests as medical devices, the US FDA has rescinded the controversial measure, finally putting an end to the saga.